Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer

Serena Ricciardi, Silverio Tomao, Filippo De Marinis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.

Original languageEnglish
Pages (from-to)781-787
Number of pages7
JournalTherapeutics and Clinical Risk Management
Volume5
Issue number1
Publication statusPublished - 2009

Fingerprint

Pemetrexed
Non-Small Cell Lung Carcinoma
cancer
Cells
Cisplatin
Histology
Toxicity
Cytotoxins
Mesothelioma
Therapeutics
Standard of Care
drug
Epithelial Cells
Placebos
Pharmaceutical Preparations

Keywords

  • First-line setting
  • Non-small cell lung cancer
  • Non-squamous carcinoma
  • Pemetrexed

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer. / Ricciardi, Serena; Tomao, Silverio; De Marinis, Filippo.

In: Therapeutics and Clinical Risk Management, Vol. 5, No. 1, 2009, p. 781-787.

Research output: Contribution to journalArticle

@article{ad4bc70b1ef14789b219eaa5e0a80810,
title = "Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer",
abstract = "Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.",
keywords = "First-line setting, Non-small cell lung cancer, Non-squamous carcinoma, Pemetrexed",
author = "Serena Ricciardi and Silverio Tomao and {De Marinis}, Filippo",
year = "2009",
language = "English",
volume = "5",
pages = "781--787",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer

AU - Ricciardi, Serena

AU - Tomao, Silverio

AU - De Marinis, Filippo

PY - 2009

Y1 - 2009

N2 - Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.

AB - Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.

KW - First-line setting

KW - Non-small cell lung cancer

KW - Non-squamous carcinoma

KW - Pemetrexed

UR - http://www.scopus.com/inward/record.url?scp=77949458607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949458607&partnerID=8YFLogxK

M3 - Article

C2 - 19851525

AN - SCOPUS:77949458607

VL - 5

SP - 781

EP - 787

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 1

ER -